JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test.

JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test.

Mass diagnosis ‘available now’

Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies.

Quotient warns global shortages of critical components could hamper efforts

To read the full article, visit: Financial Times

JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1

Link to webcast

JERSEY, Channel Islands, Feb.

JERSEY, Channel Islands, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.

C’est une revolution dans l’univers de l’analyse de sang. Quotient, une société basée à Eysins (VD), aux portes de Nyon, met sur le marché une nouvelle technique qui permet d’obtenir des résultats complets d’un échantillon avec une grande rapidité.